Executive Summary (This is a document excerpt)

Life sciences firms bought portals early, but their initial projects ran aground as departmental pilots failed to cross organizational boundaries or finance prerequisite infrastructure like user directories, security, and common taxonomy. Doubling down on next-generation investments, pharma firms must revise their portal strategy investments now and apply them to role-based processes that bridge functional boundaries. Using portals to support collaborative, ad hoc processes, large drug manufacturers will build Innovation Networks that offer big payoffs in new drug innovation and adaptive clinical trials.

Buy Risk-Free

Download and print PDF immediately. Price: US $749

Our Money-Back Guarantee: If you are not completely satisfied, return it for a full refund within three weeks of your online purchase.

Already a Forrester Client?
Log in to read this document.